• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Foghorn Therapeutics Inc. - Common Stock (NQ:FHTX)

    4.360 +0.360 (+9.00%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Foghorn Therapeutics Inc. - Common Stock

    < Previous 1 2 3 4 5 6 Next >
    Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Announces Chief Medical Officer Succession
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    What 5 Analyst Ratings Have To Say About Foghorn Therapeutics
     
    Via Benzinga
    Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Analyst Ratings for Foghorn Therapeutics
     
    Via Benzinga
    What 6 Analyst Ratings Have To Say About Foghorn Therapeutics
     
    Via Benzinga
    Analyst Expectations for Foghorn Therapeutics's Future
     
    Via Benzinga
    Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top... 
    Via Benzinga
    Schrödinger To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
    Keybanc boosted the price target for Micron Technology, Inc. (NASDAQ: MU) from $70 to $80. Keybanc analyst John Vinh maintained an Overweight rating. Micron shares rose 3.9% to $69.70 in pre-market... 
    Via Benzinga
    Foghorn Therapeutics Shifts Focus from Development Of Cancer Hopeful with Eye Cancer
    Foghorn Therapeutics Inc (NASDAQ: FHTX) announced the data from the Phase 1 dose escalation safety study of FHD-286 in  
    Via Benzinga
    Expert Ratings for Foghorn Therapeutics
     
    Via Benzinga
    Foghorn Therapeutics Earnings Perspective: Return On Capital Employed
     
    Via Benzinga
    Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Crude Oil Up 1.5%; Philips Shares Jump After Q1 Results
    U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping around 40 points on Monday. The Dow traded up 0.05% to 33,827.42 while the NASDAQ fell 0.33% to 12,032.16.... 
    Via Benzinga
    Why IDEAYA Biosciences Shares Are Trading Higher By Around 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Gainers Aclarion, Inc. (NASDAQ: ACON) shares surged 152% to $1.85 amid the publication of durability data for the company's back pain treatment. 
    Via Benzinga
    US Stocks Turn Lower; Nasdaq Dips 100 Points
    U.S. stocks turned lower midway through trading, with the Nasdaq Composite dropping around 100 points on Monday. The Dow traded down 0.19% to 33,744.92 while the NASDAQ fell 0.84% to 11,971. The S&P... 
    Via Benzinga
    More Trouble For Foghorn Therapeutics: After Blood Cancer Trial, FDA Puts Another Cancer Trial On Clinical Hold
     
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
     
    Via Benzinga
    Foghorn Therapeutics Provides an Update on FHD-609
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286, a Potent, Selective Inhibitor of BRG1 and BRM, at the 2023 American Association for Cancer Research Annual
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023
     
    Via Benzinga
    Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics to Participate at Cowen’s 43rd Annual Health Care Conference
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Why Altimmune, Foghorn Therapeutics, and Precigen Shares Crashed This Week
    Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week. 
    Via The Motley Fool
    Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.